Showing results (831-840 of 993) with videos related to

Sort By:
Pageof 100
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1995
Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitorsG Tortora, F Ciardiello, V Damiano, et al.
British Journal of Cancer|March 1, 1990
A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials CommitteeJ Carmichael, B M Cantwell, K A Mannix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2001
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinomaS K Chia, C C Wykoff, P H Watson, et al.
Cancer Research|December 15, 1991
Relationship between topoisomerase II level and chemosensitivity in human tumor cell linesA M Fry, C M Chresta, S M Davies, et al.
Cancer|January 15, 1990
Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical studyJ A Henry, A L McCarthy, B Angus, et al.
CJC Open|December 11, 2020
Exploring Occupational, Recreational, and Environmental Associations in Patients With Clinically Manifest Cardiac SarcoidosisStewart D Spence, Maria C Medor, Pablo B Nery, et al.
Journal of Pediatric Orthopedics|September 21, 2022
The Incidence of Posterolateral Tibial Plateau and Central Lateral Femoral Condylar Impaction Fractures in a Pediatric and Young Adult PopulationDavid L Bernholt, Jessica M Buchman, Aaron M Baessler, et al.
British Journal of Cancer|June 6, 2000
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazineD J Propper, J P Braybrooke, N C Levitt, et al.
Oncogene|March 18, 2014
PCK2 activation mediates an adaptive response to glucose depletion in lung cancerK Leithner, A Hrzenjak, M Trötzmüller, et al.
British Journal of Cancer|March 2, 2013
miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosisR I McCormick, C Blick, J Ragoussis, et al.
Pageof 100